Temporal effects of Palmitoylethanolamide (PEA) in modulating knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled trial
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Dose used in the study
- Two dose levels of palmitoylethanolamide against placebo. The record checked does not give the doses or the number of participants.
- Duration
- 12 weeks
- What was measured
- The WOMAC osteoarthritis index as the main measure
What the authors reported
Placebo showed the greater improvement at week 4, while the palmitoylethanolamide groups showed larger falls over the following 8 weeks. Differences in WOMAC scores were not statistically significant (p > 0.05). The high-dose group had a higher responder rate than placebo at week 12 (p = 0.034). The supplement was well tolerated.
Limits of this study
The main outcome did not differ significantly from placebo. The positive finding is a responder analysis in one dose group. The entry was checked against the abstract only, and the record did not give participant numbers, doses or funding.
Source
Entry checked against the abstract and citation held by Crossref, the DOI registry on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.